Are you Dr. Rutkowski?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 33 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
30 S Cayuga Rd
Williamsville, NY 14221Phone+1 716-632-1088Fax+1 716-632-7842
Summary
- Dr. Piotr Rutkowski, MD is a board certified anesthesiologist in Williamsville, New York. He is currently licensed to practice medicine in New York, Florida, and Wisconsin. He is affiliated with KALEIDA Health.
Education & Training
Medical College of Wisconsin Affiliated HospitalsResidency, Anesthesiology, 2010 - 2014
Jagiellonian University Medical CollegeClass of 2010
Certifications & Licensure
FL State Medical License 2022 - 2026
NY State Medical License 2015 - 2026
WI State Medical License 2011 - 2019- American Board of Anesthesiology Anesthesiology
Clinical Trials
- Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Publications & Presentations
PubMed
- 8 citationsHealth-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: R...Dirk Schadendorf, Hussein Tawbi, Evan J Lipson, F Stephen Hodi, Piotr Rutkowski
European Journal of Cancer. 2023-07-01 - 6 citationsA discrepancy between CT angiography and transesophageal echocardiographic measurements of the annular size affect long term survival following trans-catheter aortic v...Siddarth Singh, Piotr S. Rutkowski, Alexey N. Dyachkov, Vijay Iyer, Leili Pourafkari
Journal of Cardiovascular and Thoracic Research. 2021-08-25 - 785 citationsFive-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.Caroline Robert, Jean J. Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild
The New England Journal of Medicine. 2019-06-04
Press Mentions
Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline UpdateNovember 10th, 2022- Immunotherapy Drug Benefits Patients with High-Risk Local MelanomasSeptember 18th, 2021
Dermatology Today and Tomorrow: From Symptom Control to Targeted TherapyDecember 18th, 2018
